Cerebrolysin vs DSIP: what the research actually compares

Cerebrolysin is a multimodal neuropeptide preparation derived from porcine brain tissue, described in the literature as a mixture of low-molecular-weight neuropeptides and free amino acids; it is not a single defined sequence, and the evidence block supplies no formula or molecular weight for it. DSIP (delta sleep-inducing peptide) is a short endogenous neuropeptide, conventionally described by its nine-residue sequence; the evidence block supplies no sequence, formula, or molecular weight for it either. The two are therefore not the same class of material: one is a heterogeneous biological preparation, the other a discrete peptide.

The published work retrieved here centres on neurotrophic and neuroprotective signalling — for Cerebrolysin, on the neurotrophic-factor and neuroplasticity pathways invoked in stroke recovery, blood-brain barrier and endothelial integrity, and neuropathic pain models; for DSIP, on sleep-related neuroendocrine signalling. That difference in pathway focus is the single most important thing to hold onto when reading the two literatures side by side.

Research Studies

Cerebrolysin and extended-window endovascular thrombectomy

The largest formal study in this evidence block is a multicentre randomized clinical trial evaluating whether Cerebrolysin, given after successful extended-window endovascular thrombectomy, reduces brain tissue injury and supports recovery [1]. The rationale given is that patients treated 6 to 24 hours after stroke onset can benefit from clot removal, yet some remain disabled even when the blocked artery is reopened, with ongoing injury to brain tissue, small vessels, and the blood-brain barrier proposed as a contributor [1]. This is a randomized design, which matters: most of the other Cerebrolysin material here is observational or anecdotal.

Cerebrolysin and basilar artery occlusion after mechanical thrombectomy

A case report described a 67-year-old woman with multiple vascular risk factors who presented with acute basilar artery occlusion and was treated with intravenous thrombolysis followed by successful mechanical thrombectomy (TICI grade 3), with adjunctive Cerebrolysin administered subsequently [2]. Rapid neurological improvement was observed within 24 hours, with the NIHSS score falling from 7 to 2, followed by complete neurological recovery (NIHSS 0) [2]. The authors frame basilar artery occlusion as uncommon but devastating, frequently producing severe disability or death despite successful reperfusion [2]. A single case cannot separate drug effect from reperfusion effect, spontaneous recovery, or rehabilitation.

Cerebrolysin and post-stroke Wernicke's aphasia

A second case report described a 38-year-old female lawyer who developed acute Wernicke's aphasia and right-sided hemiparesis after ischemic stroke and, despite timely thrombolysis and mechanical thrombectomy, retained significant neurological deficits [3]. Early multidisciplinary rehabilitation combined with a 10-day course of Cerebrolysin was administered [3]. The paper notes that post-stroke aphasia affects roughly one-third of stroke survivors and that speech-language therapy remains the standard of care, with pharmacological agents such as Cerebrolysin proposed to enhance recovery through neuroprotection and neuroplasticity [3]. Again, the design is a single case.

Cerebrolysin and cerebral endothelial cell permeability in vitro

An in vitro study used an endothelial permeability assay to test whether exosomes released by Cerebrolysin-treated cerebral endothelial cells (Cerebro-Exos) act on dysfunctional cerebral endothelial cells [4]. Stoichiometric analysis showed marked differences in cargo profiles between Cerebro-Exos and exosomes from untreated cells (Naïve-Exos), with Cerebro-Exos highly enriched in metabolic and tight junction-related proteins [4]. Cerebro-Exos had a superior effect to Naïve-Exos on restoring endothelial cell integrity impaired by fibrin and tissue plasminogen activator [4]. This is cell-culture work and does not establish a clinical effect.

Cerebrolysin and neuropathic pain with blood-spinal cord barrier breakdown

A retraction note concerns a study of Cerebrolysin in the context of neuropathic pain exacerbation, blood-spinal cord barrier breakdown, and cord pathology following chronic intoxication with engineered silver, copper, or aluminium nanoparticles in the 50–60 nm range [5]. The retraction note is the citable record here; the underlying findings should not be treated as established.

Cerebrolysin combined with speech therapy in nonfluent aphasia

A conference abstract reports a meta-analysis of the effect of Cerebrolysin combined with speech therapy on nonfluent aphasia recovery after ischemic stroke [6]. Because the evidence block supplies only the abstract record, the pooled effect size, the number of included studies, and the heterogeneity are not available here. It should be read as a signal that a synthesis exists, not as a quantified result.

Cerebrolysin as an add-on in virtual reality neurorehabilitation

A second conference abstract examined virtual reality neurorehabilitation in acute stroke patients and the add-on effect of Cerebrolysin [7]. As with [6], the abstract record alone does not give the trial size, the comparator, or the outcome values, so no magnitude can be reported.

Cerebrolysin and 12-month functional outcomes after thrombectomy

A third conference abstract reported 12-month functional outcomes for Cerebrolysin after endovascular thrombectomy in stroke, in a propensity-matched cohort [8]. Propensity matching addresses some confounding in observational data but does not substitute for randomization; the abstract record does not supply the outcome figures.

Cerebrolysin in very early short-course use after tenecteplase and thrombectomy

A case report described very early short-course Cerebrolysin after tenecteplase and mechanical thrombectomy [9]. It notes that despite high recanalization rates with mechanical thrombectomy, large-vessel occlusion stroke results in death or dependency in more than half of patients, and that Cerebrolysin, described as a multimodal neuropeptide preparation, may attenuate ischemia-reperfusion injury and support early neurorehabilitation [9]. The report concerns an 88-year-old woman [9].

DSIP and the sleep neuroendocrine literature

The evidence block contains no study of DSIP. No published work on DSIP is supplied here, so nothing can be stated about what has been measured for it, in which model, or with what result. Any comparison of the two compounds on measured outcomes is therefore one-sided by construction: the Cerebrolysin side has retrievable studies, and the DSIP side has none in this block.

Where the two literatures stand

Two further retraction records sit in the Cerebrolysin literature: one concerning a regional comparison of the neurogenic effects of CNTF-derived peptides and Cerebrolysin in AβPP transgenic mice [10], and one concerning timed release of Cerebrolysin using drug-loaded titanate nanospheres in a Parkinson's disease model [11]. A third retraction note concerns neurotrophic effects of Cerebrolysin in the Mecp2^308/Y transgenic model of Rett syndrome [12]. These are part of the record and should be counted as such when weighing the preclinical literature.

What is not known

• No DSIP study appears in this evidence block, so no claim about DSIP's measured effects, dose-response, or model systems can be made from it.
• No sequence, molecular formula, or molecular weight is supplied for either compound here.
• The meta-analysis and the two cohort abstracts [6][7][8] are available only as abstract records; effect sizes, sample sizes, and confidence intervals are not given.
• The case reports [2][3][9] cannot distinguish compound effect from reperfusion, rehabilitation, or natural recovery.
• The in vitro endothelial work [4] does not translate to an in vivo or clinical endpoint on its own.
• Several preclinical Cerebrolysin findings have been retracted [5][10][11][12], which limits how much weight the preclinical layer can carry.

On the evidence retrieved here, the literature supports a statement about Cerebrolysin in ischemic stroke and in endothelial models, and supports no statement at all about DSIP. That is a statement about the retrieved literature, not a ranking of the compounds.

If you are reading this for personal health reasons

The materials described on this page are sold for laboratory research use only. We do not provide dosing information, administration guidance, or medical advice of any kind. Anyone considering a compound for their own use should speak with a licensed clinician.

Sources

• [1] Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy — https://clinicaltrials.gov/study/NCT06339411
• [2] Adjunctive Cerebrolysin therapy following mechanical thrombectomy for acute basilar artery occlusion: a case report — https://europepmc.org/article/PMC/PMC13474398
• [3] Cerebrolysin as an adjunct to speech-language therapy in post-stroke Wernicke's aphasia: a case report — https://europepmc.org/article/PMC/PMC13474394
• [4] Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability — https://europepmc.org/article/PMC/PMC13205112
• [5] Retraction Note: Cerebrolysin Attenuates Exacerbation of Neuropathic Pain, Blood-Spinal Cord Barrier Breakdown and Cord Pathology Following Chronic Intoxication of Engineered Ag, Cu or Al (50-60 nm) Nanoparticles — https://europepmc.org/article/PMC/PMC13179879
• [6] ABSTRACT NUMBER: ESOC2026A102 META-ANALYSIS: THE EFFECT OF CEREBROLYSIN COMBINED WITH SPEECH THERAPY ON NONFLUENT APHASIA RECOVERY AFTER ISCHEMIC STROKE — https://europepmc.org/article/PMC/PMC13146077
• [7] ABSTRACT NUMBER: ESOC2026A822 VIRTUAL REALITY NEUROREHABILITATION IN ACUTE STROKE PATIENTS AND THE ADD-ON EFFECT OF CEREBROLYSIN — https://europepmc.org/article/PMC/PMC13145624
• [8] ABSTRACT NUMBER: ESOC2026A562 CEREBROLYSIN AFTER ENDOVASCULAR THROMBECTOMY IN STROKE: 12-MONTH FUNCTIONAL OUTCOMES IN A PROPENSITY-MATCHED COHORT — https://europepmc.org/article/PMC/PMC13146562
• [9] Very Early Short-Course Cerebrolysin After Tenecteplase and Mechanical Thrombectomy: A Case Report — https://pubmed.ncbi.nlm.nih.gov/42666484/
• [10] Retraction: Regional Comparison of the Neurogenic Effects of CNTF-Derived Peptides and Cerebrolysin in AβPP Transgenic Mice — https://pubmed.ncbi.nlm.nih.gov/42015030/
• [11] Retraction Note to: Timed Release of Cerebrolysin Using Drug-Loaded Titanate Nanospheres Reduces Brain Pathology and Improves Behavioral Functions in Parkinson's Disease — https://pubmed.ncbi.nlm.nih.gov/41920231/
• [12] Retraction Note: Neurotrophic effects of Cerebrolysin in the Mecp2^308/Y transgenic model of Rett syndrome — https://pubmed.ncbi.nlm.nih.gov/41874695/